Supriya Lifescience Intrinsic Value
SUPRIYA • Healthcare
Current Stock Price
₹612.20
Primary Intrinsic Value
₹506.00
Market Cap
₹979.5 Cr
+52.5%
Upside
Median Value
₹933.75
Value Range
₹184 - ₹1401
Assessment
Trading Below Calculated Value
Safety Margin
34.4%
SUPRIYA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹506.00 | ₹404.80 - ₹607.20 | -17.3% | EPS: ₹23.00, Sector P/E: 22x |
| Book Value Method | asset | ₹1246.25 | ₹1121.62 - ₹1370.88 | +103.6% | Book Value/Share: ₹623.12, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹933.75 | ₹840.38 - ₹1027.12 | +52.5% | Revenue/Share: ₹466.88, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1224.40 | ₹1101.96 - ₹1346.84 | +100.0% | EBITDA: ₹275.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1400.78 | ₹1120.62 - ₹1680.94 | +128.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹183.66 | ₹165.29 - ₹202.03 | -70.0% | EPS Growth: 5.1%, Fair P/E: 4.1x |
| Growth Adjusted P/E | growth | ₹359.75 | ₹323.78 - ₹395.73 | -41.2% | Revenue Growth: 8.6%, Adj P/E: 15.6x |
| ROE Based Valuation | profitability | ₹1224.40 | ₹1101.96 - ₹1346.84 | +100.0% | ROE: 18.6%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹567.86 | ₹511.07 - ₹624.65 | -7.2% | EPS: ₹23.00, BVPS: ₹623.12 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
SUPRIYA Intrinsic Value Analysis
What is the intrinsic value of SUPRIYA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Supriya Lifescience (SUPRIYA) is ₹933.75 (median value). With the current market price of ₹612.20, this represents a +52.5% variance from our estimated fair value.
The valuation range spans from ₹183.66 to ₹1400.78, indicating ₹183.66 - ₹1400.78.
Is SUPRIYA undervalued or overvalued?
Based on our multi-method analysis, Supriya Lifescience (SUPRIYA) appears to be trading below calculated value by approximately 52.5%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.24 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 18.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 36.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.67x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Supriya Lifescience
Additional stock information and data for SUPRIYA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹165 Cr | ₹89 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹113 Cr | ₹26 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹64 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹49 Cr | ₹19 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹76 Cr | ₹53 Cr | Positive Free Cash Flow | 8/10 |